| 7.7 0.995 (14.84%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.51 |
1-year : | 12.27 |
| Resists | First : | 9 |
Second : | 10.51 |
| Pivot price | 7.19  |
|||
| Supports | First : | 7.24 |
Second : | 6.15 |
| MAs | MA(5) : | 6.77 |
MA(20) : | 7.49 |
| MA(100) : | 7.19 |
MA(250) : | 8.92 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 26.2 |
D(3) : | 14.1 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 26.6 | Low : | 0.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PASG ] has closed below upper band by 25.7%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8 - 8.03 | 8.03 - 8.07 |
| Low: | 6.28 - 6.31 | 6.31 - 6.34 |
| Close: | 7.64 - 7.69 | 7.69 - 7.75 |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Mon, 10 Nov 2025
Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu - GuruFocus
Mon, 10 Nov 2025
PASG: Clinical trial progress, reduced net loss, and strong cash position support future milestones - TradingView
Mon, 10 Nov 2025
Passage Bio (NASDAQ: PASG) narrows net loss to $7.7M, y/y from $19.3M as costs decline - Stock Titan
Mon, 10 Nov 2025
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights - Yahoo Finance
Fri, 07 Nov 2025
Passage Bio Inc expected to post a loss of $2.80 a share - Earnings Preview - TradingView
Wed, 05 Nov 2025
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 55.4 (%) |
| Shares Short | 82 (K) |
| Shares Short P.Month | 82 (K) |
| EPS | 39.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -88.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -16.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | 0.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|